SCHEMBL2645946

SCHEMBL2645946

C=Cc1ccc(C(=O)NCCC(=O)OCC)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.53
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ TAS1R3 Q7RTX0 2/20 0.49
▸ TAS1R1 Q7RTX1 2/20 0.49
▸ PRSS1 P07477 1/20 0.48
▸ CTSG P08311 1/20 0.48
▸ CTRB1 P17538 1/20 0.48
▸ CMA1 P23946 1/20 0.48
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ CYP1A2 P05177 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ NAMPT P43490 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2650710 0.87 MAPT (0.54) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL14679110 0.85 LMNA (0.58) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL2273609 0.84 MAPT (0.56) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL14172931 0.82 MAPT (0.55) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL8879612 0.82 MAPT (0.55) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL23782641 0.82 HPGD (0.61) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL718603 0.82 LMNA (0.56) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL27439930 0.82 PRSS1 (0.71) MAPTSMN1; SMN2PRSS1CTSGCTRB1
SCHEMBL27353786 0.82 TAS1R3 (0.60) TAS1R3TAS1R1NPC1RAB9AKMT2A
SCHEMBL11901150 0.80 MAPT (0.53) MAPTSMN1; SMN2PRSS1CTSGCTRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209928-A1 Glucagon receptor antagonists/inverse agonists ABBOTT LABORATORIES 2004-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209928-A1 Glucagon receptor antagonists/inverse agonists GLP1R, GPR119, GCGR MAPT 4677/4885SMN1; SMN2 2072/4885TAS1R3 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback